Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.69 |
| ▸ | GAA | P10253 | 2/20 | 0.69 |
| ▸ | DBH | P09172 | 1/20 | 0.69 |
| ▸ | RECQL | P46063 | 1/20 | 0.69 |
| ▸ | LCK | P06239 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | HSD17B14 | Q9BPX1 | 1/20 | 0.38 |
| ▸ | HTR1B | P28222 | 2/20 | 0.37 |
| ▸ | RARB | P10826 | 1/20 | 0.37 |
| ▸ | RARG | P13631 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12418686 | 0.90 | KDM4E (0.63) | KDM4EGAADBHRECQLLCK | |
| SCHEMBL12317627 | 0.85 | KDM4E (0.58) | KDM4EGAADBHRECQLLCK | |
| SCHEMBL16811768 | 0.85 | ALDH1A1 (0.54) | KDM4EGAADBHRECQLALDH1A1 | |
| SCHEMBL8745697 | 0.85 | KDM4E (0.53) | KDM4EGAADBHRECQLLCK | |
| SCHEMBL19090508 | 0.82 | KDM4E (0.55) | KDM4EGAADBHRECQLALDH1A1 | |
| SCHEMBL759389 | 0.82 | CES2 (0.61) | KDM4EGAADBHRECQLALDH1A1 | |
| SCHEMBL8471397 | 0.82 | KDM4E (1.00) | KDM4EGAADBHRECQLFFAR1 | |
| SCHEMBL15850532 | 0.82 | KDM4E (0.47) | KDM4EGAADBHRECQLLCK | |
| SCHEMBL3260971 | 0.81 | CYP2A6 (0.56) | KDM4EGAADBHRECQLALDH1A1 | |
| SCHEMBL4025692 | 0.80 | KDM4E (0.49) | KDM4EGAADBHRECQLALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220387394-A1 | METHODS OF TREATING CANCER USING ANDROGEN RECEPTOR ANTAGONISTS | GARVAN INSTITUTE OF MEDICAL RES (AU) | 2022-12-08 | — | — | US | disclosed |
| US-20210292410-A1 | TREATMENT PARADIGM FOR AN ANTI-CD19 ANTIBODY AND VENETOCLAX COMBINATION TREATMENT | INCYTE CORPORATION | 2021-09-23 | — | — | US | disclosed |
| US-20210154209-A1 | COMPOSITIONS FOR TREATMENT OF BREAST AND PROSTATE CANCER | KEMBI THERAPEUTICS PTY LTD (AU) | 2021-05-27 | — | — | US | disclosed |
| WO-2019182743-A1 | COMPOSITIONS FOR THE TREATMENT OF BRAIN TUMORS | INNOCRIN PHARMACEUTICALS, INC. (US) | 2019-09-26 | — | — | WO | disclosed |
| WO-2019113301-A1 | COMPOSITIONS FOR THE TREATMENT OF BREAST AND PROSTATE CANCER | INNOCRIN PHARMACEUTICALS, INC. (US) | 2019-06-13 | — | — | WO | disclosed |
| WO-2019113312-A1 | ANTICANCER COMPOUND PROCESS | INNOCRIN PHARMACEUTICALS, INC. (US) | 2019-06-13 | — | — | WO | disclosed |
| EP-3483147-A1 | METALLOENZYME INHIBITOR COMPOUNDS | Innocrin Pharmaceuticals, Inc. (US) | 2019-05-15 | — | — | EP | disclosed |
| US-20180221364-A1 | METALLOENZYME INHIBITOR COMPOUNDS | INNOCRIN PHARMACEUTICALS, INC. | 2018-08-09 | — | — | US | disclosed |
| US-20170143694-A1 | METALLOENZYME INHIBITOR COMPOUNDS | INNOCRIN PHARMACEUTICALS, INC. | 2017-05-25 | — | — | US | disclosed |
| US-20170143694-A1 | METALLOENZYME INHIBITOR COMPOUNDS | INNOCRIN PHARMACEUTICALS, INC. | 2017-05-25 | — | — | US | disclosed |
| US-20120309800-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2012-12-06 | — | — | US | disclosed |
| US-20120309800-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2012-12-06 | — | — | US | disclosed |
| US-20120129886-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2012-05-24 | — | — | US | disclosed |
| US-20120129886-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2012-05-24 | — | — | US | disclosed |
| WO-2012064943-A2 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2012-05-18 | — | — | WO | disclosed |
| WO-2011082245-A2 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2011-07-07 | — | — | WO | disclosed |
| US-6903114-B2 | Derivatives of naphthalene with COMT inhibiting activity | ORION CORPORATION (FI) | 2005-06-07 | — | — | US | disclosed |
| US-20040034011-A1 | Derivatives of naphthalene with comt inhibiting activity | ORION CORPORATION (FI) | 2004-02-19 | — | — | US | disclosed |
| EP-1317411-A1 | DERIVATIVES OF NAPHTHALENE WITH COMT INHIBITING ACTIVITY | ORION CORPORATION (FI) | 2003-06-11 | — | — | EP | disclosed |
| WO-2002022551-A1 | DERIVATIVES OF NAPHTHALENE WITH COMT INHIBITING ACTIVITY | ORION CORPORATION (FI) | 2002-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180221364-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | KDM4E 3322/4885GAA 6/4885DBH 598/4885 |
| US-20040034011-A1 | Derivatives of naphthalene with comt inhibiting activity | COMT, CYP1A1, CYP1B1 | KDM4E 2965/4885GAA 201/4885DBH 119/4885 |
| US-20210292410-A1 | TREATMENT PARADIGM FOR AN ANTI-CD19 ANTIBODY AND VENETOCLAX COMBINATION TREATMENT | CD22, MLLT1, BTK | KDM4E 221/4885GAA 2360/4885DBH 1044/4885 |
| US-20170143694-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | KDM4E 3322/4885GAA 6/4885DBH 598/4885 |
| US-20120129886-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | KDM4E 3322/4885GAA 6/4885DBH 598/4885 |
| US-20210154209-A1 | COMPOSITIONS FOR TREATMENT OF BREAST AND PROSTATE CANCER | SHBG, NR5A1, KLK3 | KDM4E 1156/4885GAA 3115/4885DBH 1740/4885 |
| US-20120309800-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | KDM4E 3322/4885GAA 6/4885DBH 598/4885 |
| US-20220387394-A1 | METHODS OF TREATING CANCER USING ANDROGEN RECEPTOR ANTAGONISTS | AR, GNRHR, KLK3 | KDM4E 2706/4885GAA 2348/4885DBH 1945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.